Sionna Therapeutics, Inc. (SION) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Sionna Therapeutics reported revenue of $0. Net income was -$75.3M, or -$1.88 per diluted share. Operating activities generated -$66.3M of cash, leaving -$66.7M of free cash flow. At fiscal year end, Sionna Therapeutics held $326.0M in total assets against $19.1M in total liabilities, including $58.5M of cash and equivalents.
Open the full interactive Sionna Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Sionna Therapeutics Key Stats
| Share Price | $4.38 |
|---|---|
| Market Cap | $197.8M |
| 52-Week Range | $4.38 – $51.04 |
| Shares Outstanding | 45.1 million (basic, 2026 Q2) |
Sionna Therapeutics Income Statement
| FY 2025 | |
|---|---|
| Revenue | $0 |
| Operating Income | -$89.0M |
| Pre-Tax Income | -$75.3M |
| Income Tax | $0 |
| Net Income | -$75.3M |
| Diluted EPS | -$1.88 |
Sionna Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$20.3M | -$20.4M | -$26.8M | -$29.9M |
| Diluted EPS | -$0.46 | -$0.51 | -$0.60 | -$0.66 |
Sionna Therapeutics Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $58.5M |
| Current Assets | $241.4M |
| Total Assets | $326.0M |
| Current Liabilities | $11.7M |
| Total Liabilities | $19.1M |
| Shareholders' Equity | $306.8M |
Sionna Therapeutics Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$66.3M |
| Cash From Investing | -$118.7M |
| Cash From Financing | $205.7M |
| Free Cash Flow | -$66.7M |
Figures from Sionna Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Sionna Therapeutics financials page for every line item.
Sionna Therapeutics Company Profile
| Ticker | SION |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Waltham, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0002036042 |
Frequently Asked Questions
What was Sionna Therapeutics' revenue in fiscal 2025?
Sionna Therapeutics (SION) reported revenue of $0 for fiscal 2025.
What was Sionna Therapeutics' net income in fiscal 2025?
Sionna Therapeutics reported net income of -$75.3M for fiscal 2025.
What was Sionna Therapeutics' earnings per share (EPS) in fiscal 2025?
Sionna Therapeutics' diluted EPS was -$1.88 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Sionna Therapeutics generate in fiscal 2025?
Sionna Therapeutics generated -$66.7M of free cash flow in fiscal 2025.
What was Sionna Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Sionna Therapeutics reported revenue of $0.
How many shares of Sionna Therapeutics are outstanding?
Sionna Therapeutics reported a weighted average of 45.1 million basic shares outstanding in 2026 Q2.
What is Sionna Therapeutics' market cap?
Based on its latest closing price, Sionna Therapeutics (SION) has a market capitalization of about $197.8M.
When does Sionna Therapeutics' fiscal year end?
Sionna Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Sionna Therapeutics headquartered?
Sionna Therapeutics lists its business address in Waltham, Massachusetts in its SEC filings.